Gradipore and Serologicals Corporation announced a development agreement for evaluating the application of Gradipore's Gradiflow separations technology for the isolation of plasma proteins intended for use as diagnostic reagents, culture medium supplements, or for therapeutic indications. The agreement will generate immediate revenue for Gradipore.

Upon successful completion of the evaluation to the specified requirements of Serologicals, Gradipore and Serologicals will discuss a more extensive commercial agreement for the purification and commercialization of other plasma proteins.

"Mass producing medically-relevant products was the intention for the Gradiflow system, and we have the highest confidence that this agreement with Serologicals will clearly demonstrate this," said Gradipore CEO, Robert E. Lieb. "Also of importance is the fact that this deal expands the diversity of biological applications for the Gradiflow technology."

"The Gradiflow technology offers an attractive alternative to the existing technologies of fractionation and chromatography with potentially higher yields at similar or superior quality," said David A. Dodd President and CEO of Serologicals Corporation. "Serologicals is excited to start this collaboration and have access to this promising platform in its continuous pursuit of the manufacture of the highest quality biologics."